2010 Fiscal Year Final Research Report
Development of new therapy for type 2 diabetes targeting sphingolipid receptor on pancreatic beta cell
| Project/Area Number |
21790858
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Metabolomics
|
|---|
| Research Institution | Hirosaki University |
|---|
Principal Investigator |
MIZUKAMI Hiroki Hirosaki University, 大学院・医学研究科, 講師 (00374819)
|
|---|
| Project Period (FY) |
2009 – 2010
|
| Keywords | スフィンゴ脂質 / β細胞 / 2型糖尿病 / G蛋白共益受容体 / S1P1 |
|---|
| Research Abstract |
To evaluate the function of sphingolipid signaling in pancreatic β cells, β cell specific S1P1 knocked out mouse was generated using Cre-Lox P system. βS1P1KO showed no apparent phenotype in vivo. Forskolin potentiated insulin secretion was promoted in isolated islet of βS1P1KO compared to control. In whole islet patch clump, forskolin stimulated hyper-oscillation of Ca^<2+> was observed inβS1P1KO islet even under 500nM S1P. In islet transplantation experiment, marginal number of βS1P1KO islets (100) successively lowered glucose level in STZ induced type 1 diabetic model mouse, but not of control islets. Collectively, inhibition of S1P1 signaling in β cells can lead to protection against β cell injury and lead to a new type of β cell therapy in diabetes.
|
